101990-45-8

Basic information

• Product Name: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)
• Synonyms: Pyridine, 2-bromo-5-(bromomethyl)- (9CI);2-Bromo-5-(bromomethyl)pyridine;6-Bromo-3-pyridylmethyl bromide;2-Bromo-5-(bromomethyl)pyridine 96%;3-Pyridineacetonitrile, 6-bromo-;2-Bromo-5-(bromomethyl)
• CAS NO: 101990-45-8
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Product Categories: PYRIDINE;OLED materials,pharm chemical,electronic
• Mol File: 101990-45-8.mol

Chemical Properties

• Melting Point: 60-65°C
• Boiling Point: 296.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.955
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.12±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(101990-45-8)
• EPA Substance Registry System: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(101990-45-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• RIDADR: UN 3335
• WGK Germany: 3
• Hazardous Substances Data: 101990-45-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 2-bromo-5-(bromomethyl)(9CI) is used as a precursor in the synthesis of various pharmaceuticals. Its unique structure and functional groups make it a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, Pyridine, 2-bromo-5-(bromomethyl)(9CI) serves as a precursor for the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and functional groups contribute to the creation of effective and targeted agrochemicals for crop protection.
Used in Fine Chemicals Industry:
Pyridine, 2-bromo-5-(bromomethyl)(9CI) is also utilized in the synthesis of other fine chemicals, including specialty chemicals and intermediates for various applications. Its versatility and reactivity make it a valuable component in the development of complex molecules for diverse industries.

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 23100-12-1 6-chloronicotinylaldehyde 
• 149806-06-4 6-bromonicotinaldehyde 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 
• 843646-70-8 (6-bromopyridin-3-yl)methyl methanesulfonate 
• 128-08-5 N-Bromosuccinimide 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 7789-60-8 phosphorus tribromide 
• 70258-18-3 2-chloro-5-(chloromethyl)pyridine 

Downstream Products

• 248924-73-4 2-(benzhydrylidene-amino)-3-(6-furan-2-yl-pyridin-3-yl)-propionic acid ethyl ester 
• 248924-58-5 2-(benzhydrylidene-amino)-3-(6-furan-3-yl-pyridin-3-yl)-propionic acid ethyl ester 
• 248924-35-8 2-(benzhydrylidene-amino)-3-[2,3']bipyridinyl-5-yl-propionic acid ethyl ester 
• 248924-42-7 2-(benzhydrylidene-amino)-3-(6-thiophen-2-yl-pyridin-3-yl)-propionic acid ethyl ester 
• 248924-15-4 2-(benzhydrylidene-amino)-3-(6-thiophen-3-yl-pyridin-3-yl)-propionic acid ethyl ester 
• 516491-40-0 2-(benzhydrylidene-amino)-3-(6-phenyl-pyridin-3-yl)-propionic acid ethyl ester 
• 516491-49-9 3-[6-(3-amino-phenyl)-pyridin-3-yl]-2-(benzhydrylidene-amino)-propionic acid ethyl ester 
• 248924-63-2 2-(benzhydrylidene-amino)-3-[6-(3-nitro-phenyl)-pyridin-3-yl]-propionic acid ethyl ester 
• 516491-41-1 2-[(1-tert-butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-(6-phenyl-pyridin-3-yl)-propionic acid ethyl ester 
• 516491-42-2 2-{[1-((R)-2-Bromo-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(6-phenyl-pyridin-3-yl)-propionic acid ethyl ester 
• 516491-57-9 2-[(1-tert-butoxycarbonylamino-cyclopentanecarbonyl)-amino]-3-[6-(3-nitro-phenyl)-pyridin-3-yl]-propionic acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

The chemokine receptor CXCR4/stromal cell-derived factor-1 (SDF-1: CXCL12) signaling axis represents a crucial drug target due to its relevance to several diseases such as HIV-1 infection, cancer, leukemia, and rheumatoid arthritis. With the aim of enhancing the binding affinity and anti-HIV activity of a potent CXCR4 ligand as a lead, 23 low molecular weight compounds containing dipicolylamine (Dpa) and cyclam cationic moieties with varying spacers and spatial positioning were designed, synthesized and biologically evaluated. All of the synthesized compounds screened at 1.0 μM in the NanoBRET assay system exhibited >70% inhibition of the binding of a competitive probe TAMRA-Ac-TZ14011 (10 nM) to CXCR4 in the presence of zinc (II) ion. Furthermore, selected compounds 3, 8, 9, 19 and 21 with spatial distances between the next carbon to Dpa and the next carbon to cyclam within the range of 6.5–7.5 ? showed potent binding affinity selective for CXCR4 with IC50 values of 1.6, 7.9, 5.7, 3.5 and 4.5 nM, respectively, with corresponding high anti-HIV activity with EC50s of 28, 13, 21, 28 and 61 nM, respectively, in the presence of zinc (II) ion. Some compounds with remarkably more potent CXCR4-binding affinity than that of an initial lead were obtained. These compounds interact with different but overlapping amino acid residues of CXCR4. The present studies have developed new low molecular weight CXCR4 ligands with high CXCR4-binding and anti-HIV activities, which open avenue into the development of more potent CXCR4 ligands.

Substituted dipyridylethenes and -ethynes and key pyridine building blocks

Various new 2,5-disubstituted pyridines were prepared. The 2-substituted 5-formylpyridines 8, 15a-b were obtained by reduction of the nicotinic acid 3, hydrolysis of the bis(morpholino)methylpyridine 6 or the reaction of 5-bromopyridines 12 and 14 with lithium butoxide in DMF. Dipyridylethenes 16a-b,e were synthesized by Wadsworth-Emmons reaction with pyridyl phosphonate 7 or by coupling of the aldehydes by McMurry reaction to the ethenes 16c-d. After bromination of the C = C double bond of the dipyridylethenes 16a-d, dipyridylacetylenes 18a-d were obtained via elimination of the 1,2-dipyridyl-1,2-dibromoethanes 17a-d.

Alternative approach to the free radical bromination of oligopyridine benzylic-methyl group

We have undertaken a study on the influence of three solvents on the photobromination of two picolines. It shows that dichloromethane and benzene are better solvents than the classical carbon tetrachloride. The obtention of a good free radical bromination is described using aqueous biphasic media.

A comparison of the binding of three series of nicotinic ligands

A total of 24 aryl-substituted analogues of nicotine (1a) and two related series of nicotinic ligands, aminomethylpyridines 3 and ether analogues 8, were examined to determine if they bind at α4β2 nACh receptors in a common manner. A modest correlation (r=0.785) was found between the affinities of the nicotine analogues and derivatives of 3, but little correlation (r=0.348) was found with analogues 8. However, a modest correlation (r=0.742) exists between the binding of analogues 3 and 8. It seems that 1-series and 8-series compounds bind differently but that the 3-series compounds share some intermediate binding similarity with both.

Pyridineacetamide derivative serving as CDK inhibitor, and preparation method and application thereof

The invention belongs to the technical field of pyridineacetamide derivatives, and particularly relates to a pyridineacetamide derivative serving as a CDK inhibitor and a preparation method and application of the pyridine acetamide derivative. The pyridineacetamide derivative shows excellent CDK9/CDK7 enzyme inhibitory activity, and can be used for preparing drugs used for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors such as breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF

Disclosed is a compound as shown in general formulas (I) or (II) and a pharmaceutically acceptable salt, an isomer or a mixture form thereof, a solvate, a polymorph, a stable isotope derivative, or a prodrug of the same. The compound of the present invention has CDK kinase inhibitory activity and can be used in treating a disease related to CDK kinase, such as a cancer.

Preparation method of 2-bromine-5-formylpyridine

The invention relates to the field of fine chemical industry and particularly relates to a preparation method of 2-bromine-5-formylpyridine. The preparation method comprises the following steps: (1) performing an oxidation reaction; (2) performing a bromination reaction. In the preparation method provided by the invention, 2-chlorine-5-chloromethyl pyridine is taken as a raw material, and the 2-bromine-5-formylpyridine is prepared by two steps of reactions: the oxidation reaction and the bromination reaction, so that the method is simple in technological operation, mild and safe in reaction conditions, low in cost of the raw material, high in reaction conversion rate, high in yield and easy in extraction of a product, therefore, the method is more suitable for safe industrial production and has greater implementation value and social and economic benefits.

HETEROARYL-CARBOXAMIDES AS HISTONE DEMETHYLASE INHIBITORS

The invention relates to heteroaryl-carboxamides as described herein, useful as histone demethyiase inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy, including e.g., in the treatment of cancer.

ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

2-bromo-5-formyl-pyridine preparation method

The invention relates to the field of fine chemical engineering, in particular to a 2-bromo-5-formyl-pyridine preparation method. The method includes steps: 1) subjecting 2-chloro-5-chloromethylpyridine to bromination reaction in presence of a bromination reagent to obtain 2-bromo-5-bromomethylpyridine; 2) subjecting 2-bromo-5-bromomethylpyridine to oxidation reaction under action of an oxidation reagent and alkali metal salt to obtain 2-bromo-5-formyl-pyridine. According to the preparation method, 2-bromo-5-formyl-pyridine is prepared from 2-chloro-5-chloromethylpyridine through a two-step reaction of bromination and oxidation, technical simplicity in operation, safe and mild reaction conditions, low raw material cost, high reaction conversion rate, high yield and easiness in product extraction are realized. Therefore, the method is suitable for industrial safety production and high in implementation value and social economical benefits.